Statistical considerations for pediatric multidrug-resistant tuberculosis efficacy trials.

about

Statistical considerations for pediatric multidrug-resistant tuberculosis efficacy trials.

Item

http://www.wikidata.org/entity/Q53692122

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Statistical considerations for ...... tuberculosis efficacy trials.

@en

Statistical considerations for ...... tuberculosis efficacy trials.

@nl

type

Item

label

Statistical considerations for ...... tuberculosis efficacy trials.

@en

Statistical considerations for ...... tuberculosis efficacy trials.

@nl

prefLabel

Statistical considerations for ...... tuberculosis efficacy trials.

@en

Statistical considerations for ...... tuberculosis efficacy trials.

@nl

P1476

Statistical considerations for ...... tuberculosis efficacy trials.

@en

P2093

A J Garcia-Prats

http://www.w3.org/2001/XMLSchema#string

G Montepiedra

http://www.w3.org/2001/XMLSchema#string

J A Seddon

http://www.w3.org/2001/XMLSchema#string

S Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.

Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Explanatory and pragmatic attitudes in therapeutical trials.

A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis

Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).

Speeding up the evaluation of new agents in cancer.

Adaptive randomization for clinical trials.

Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis.

Totality of outcomes: A different paradigm in assessing interventions for treatment of tuberculosis.

Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.

P304

34-39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5588/IJTLD.17.0358

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29665951

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

P932

6086568

http://www.w3.org/2001/XMLSchema#string